Northern Trust Corp grew its stake in GSK plc (NYSE:GSK - Free Report) by 16.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,060,255 shares of the pharmaceutical company's stock after purchasing an additional 287,211 shares during the quarter. Northern Trust Corp owned about 0.10% of GSK worth $69,678,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Dorsey & Whitney Trust CO LLC boosted its holdings in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock worth $389,000 after buying an additional 278 shares during the last quarter. GC Wealth Management RIA LLC boosted its stake in GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after acquiring an additional 353 shares during the last quarter. Jacobi Capital Management LLC grew its holdings in GSK by 3.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after purchasing an additional 389 shares during the period. Gladstone Institutional Advisory LLC increased its stake in GSK by 3.4% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after purchasing an additional 407 shares in the last quarter. Finally, CENTRAL TRUST Co boosted its position in shares of GSK by 5.6% during the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock worth $262,000 after purchasing an additional 414 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
GSK has been the subject of a number of recent analyst reports. BNP Paribas began coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Hsbc Global Res raised GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.
Read Our Latest Research Report on GSK
GSK Price Performance
NYSE GSK opened at $38.87 on Tuesday. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The firm's 50 day moving average is $37.71 and its 200-day moving average is $36.00. The company has a market capitalization of $80.20 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.
GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.43 EPS. Equities research analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.
GSK Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a yield of 4.34%. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio (DPR) is currently 86.60%.
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
